In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
400 News Items found
MSK internal medicine specialist Deborah Korenstein
Q&A
Helping Doctors "Do No Harm" by Addressing Medical Test Overuse

Learn how MSK is clarifying how unnecessary medical tests can harm a patient's well-being.
Dr. Michael Overholtzer speaks to students.
Meet the 2024 Graduates of the Gerstner Sloan Kettering Graduate School

Ten scientists are poised to receive their PhD degrees from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences. Their years of dedication and training will be recognized on May 15, 2024, as part of Memorial Sloan Kettering’s 45th annual academic convocation.
Colorful illustration of people overlaid on a world map
Finding
Genetic Variations Help Explain Why Immunotherapy Works Differently in Different People

A new study reports a possible way to quantify how efficient the immune system is at detecting cancer, and therefore how likely it is that a person will respond to immunotherapy.
Radiation oncologist and CyberKnife expert Abraham Wu
Ask the Expert
Why Am I Hearing So Much About CyberKnife?

CyberKnife is a brand name for one of several available stereotactic radiosurgery devices that deliver radiation with linear accelerators. MSK uses a similar device, made by a company called Varian, that destroys tumors with extremely precise, very intense doses of radiation.
Reicy Bobadilla stands in front of a window with the MSK logo on it
What You Should Know About Mesothelioma in Younger Patients

A new study is challenging the perception that mesothelioma affects only older men. Learn why MSK experts say the medical community should be aware of this rare cancer's early symptoms.
Dr. Robert Motzer speaks to a patient
Making Progress in Genitourinary Cancers: MSK Physicians Share Research Advances at Annual ASCO GU Symposium

MSK's Robert Motzer presented positive data from a phase III randomized study that assessed two different treatment combinations as first-line therapies that may benefit people with advanced kidney cancer.
Two Fred’s Team runners wearing orange shirts in a crowd
Your Impact: The Society, Fred’s Team, and Virtual Health Education Seminars

Learn about how our donor community is funding life-changing cancer research at Memorial Sloan Kettering and ensuring a brighter future for people with cancer around the world.
Memorial Sloan Kettering researchers Luc Morris and Nils Weinhold
Machine Learning Approach Takes MSK Researchers Beyond Known Method to Predict Immunotherapy Response

Learn about recent research led by MSK physician-scientist Luc Morris, who is trying to better predict who will benefit from immunotherapy.
A researcher working in an MSK lab
MSK Research Highlights, December 16, 2025

New MSK research finds a way to package protein-degrading drugs called PROTACs into nanoparticles that target blood vessels within solid tumors; identifies genomic markers that predict whether precancerous blood conditions will turn into multiple myeloma; develops a data-driven approach that could catch lymphedema earlier; and shows that nurse-led palliative care delivered by phone could serve as a scalable model.
Pattie Fuller smiles while wearing a pink plaid poncho
New Treatment for Metastatic (Stage 4) Melanoma: TIL Immunotherapy  

After immunotherapy and targeted therapy failed to bring a patient's melanoma under control, MSK doctors offered her a new treatment called tumor-infiltrating lymphocyte, or TIL, therapy.